Recro Pharma Inc. Daily Stock Analysis

Daily Stock Analysis, REPH, Recro Pharma Inc, priceseries

Recro Pharma Inc. Daily Stock Analysis
Stock Information
Open
1.76
Close
1.70
High
1.81
Low
1.70
Previous Close
1.75
Daily Price Gain
-0.05
YTD High
1.83
YTD High Date
Feb 14, 2022
YTD Low
1.42
YTD Low Date
Jan 31, 2022
YTD Price Change
-0.04
YTD Gain
-2.30%
52 Week High
3.94
52 Week High Date
Mar 16, 2021
52 Week Low
1.38
52 Week Low Date
Dec 6, 2021
52 Week Price Change
-1.61
52 Week Gain
-48.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 14. 2017
7.06
Oct 6. 2017
7.94
16 Trading Days
12.45%
Link
LONG
Nov 16. 2017
7.87
Dec 5. 2017
8.56
12 Trading Days
8.88%
Link
LONG
Feb 26. 2018
7.99
Mar 12. 2018
8.91
10 Trading Days
11.45%
Link
LONG
Mar 13. 2018
9.31
Mar 23. 2018
9.84
8 Trading Days
5.67%
Link
LONG
Aug 16. 2018
5.22
Aug 27. 2018
5.57
7 Trading Days
6.66%
Link
LONG
Aug 29. 2018
5.64
Sep 17. 2018
7.15
12 Trading Days
26.66%
Link
LONG
Dec 31. 2018
6.37
Jan 22. 2019
7.00
14 Trading Days
9.90%
Link
LONG
Aug 7. 2019
8.74
Aug 27. 2019
10.42
14 Trading Days
19.15%
Link
LONG
Oct 15. 2019
10.33
Dec 5. 2019
16.25
36 Trading Days
57.31%
Link
LONG
Nov 13. 2020
1.88
Dec 3. 2020
2.18
13 Trading Days
15.74%
Link
LONG
Jan 19. 2021
3.03
Jan 27. 2021
3.20
6 Trading Days
5.53%
Link
LONG
Feb 2. 2021
3.45
Feb 26. 2021
3.98
17 Trading Days
15.36%
Link
LONG
Aug 6. 2021
1.89
Aug 31. 2021
2.38
17 Trading Days
25.73%
Link
Company Information
Stock Symbol
REPH
Exchange
NasdaqCM
Company URL
http://www.recropharma.com
Company Phone
(484) 395-2400
CEO
Gerri Henwood
Headquarters
Pennsylvania
Business Address
490 LAPP ROAD, MALVERN, PA 19355
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001588972
About

Recro Pharma, Inc. is a pharmaceutical company, whcih is focused on products for hospitals and ambulatory care settings. The company is developing non-opioid products for treatment of serious acute pain. It offers drug solutions for cancer, musculoskeletal disorders and peripheral neuropathy, cancer breakthrough and acute post-operative pain. The company's products include Dex-INR and Fadolmidine, which is under development. Recro Pharma was founded by Geraldine A. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Description

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading